

# Longevity Industry in UK

LANDSCAPE OVERVIEW Q4 2018



# Longevity Industry in UK / Landscape Overview Q4 2018

Mind Map Longevity Industry in UK	3	<b>APPENDICES &amp; PROFILES</b>	
Advisors	6	260 Companies: Longevity in UK	236
Institutional Partners	7	250 investors: Longevity in UK	500
Executive Summary	8	Articles on Longevity Published by British Scientists	754
Preface: Recent UK Longevity Industry Developments - An Insight on Q4 2018	20	Books on Longevity Published in UK	806
<b>Chapter I:</b> UK Longevity Industry Landscape Overview	41	UK Longevity Scientific Journals	858
<b>Chapter II:</b> History of Geroscience in UK	66	UK Longevity Non-Profit Organisations	885
<b>Chapter III:</b> Current State of Longevity Industry in UK	78	UK Longevity Influencers	937
<b>Chapter IV:</b> The Need for an All-Party Parliamentary Group on Longevity	115	UK Universities and Research Labs	996
<b>Chapter V:</b> Global Longevity Landscape Overview	123	UK Longevity Conferences	1023
<b>Chapter VI:</b> Media and Conferences	159	UK Longevity Journalists	1045
<b>Chapter VII:</b> Economics of Longevity in the UK	197	Disclaimer	1080

1000+

Pages

3

New  
Chapters

260

Companies

250

Investors

50

Non-Profit  
Foundations

25

Research  
Centres

Aging Analytics Agency announces the publication of an analytical report - Longevity Industry in UK, Second Edition, over 1000 pages in length. Although the First Edition of the report was published just six months ago, Aging Analytics Agency was compelled to produce the Second Edition in response to the rapid Longevity industry progress seen in the United Kingdom over this short time period. This new Second Edition features in-depth profiles of 260 UK Longevity companies and 250 UK Longevity investors, and three new chapters: an overview of recent Longevity industry developments in Q4 of 2018, a chapter outlining the rationale for the establishment of an All-Party Parliamentary Group on Longevity to better coordinate cross-industry efforts and initiatives, and a chapter focusing on the economics of Longevity in the UK.



# Longevity Industry in UK, Second Edition

1000+ Page Second Edition of Longevity Industry in UK Analytical Report by Aging Analytics Agency

The central role of technology in improving the lives of the elderly has been generally recognised at a government level, however, efforts to intelligently address this issue by acknowledging Healthy Longevity as a metric in itself are currently insufficient.

2018 has seen an unprecedented rise in the level of Longevity Industry activities and developments, as well as a growth of interest in the topic of Longevity from investors, analysts and leading business media. The number of Longevity-focused startups continues to grow at an exponential rate, as well as the number of investors. We are also witnessing the growing convergence of Longevity and advanced biomedicine and preventive medicine generally. While 2017 was the dawn of the Longevity Industry, 2018 can clearly be seen as the year of its indisputable rise into mainstream prominence and maturity.

The UK Government also needs to work proactively to form overarching industry bodies to direct, guide and govern ongoing developments in the UK Longevity Industry, just as they did for their AI Industry through the AI Industrial National Strategy, the formation of an All-Party Parliamentary Group on AI and the formation of a UK Government Office for Artificial Intelligence.

## Rapid Longevity Industry Progress Since First Edition of Our Longevity in UK Report Released in Q2 2018

In July 2018, Aging Analytics Agency published an analytical report titled “Longevity Industry in UK Landscape Overview 2018”. This regional case study sought to document what made the UK a fertile ground to become a global Longevity Industry Hub, and how that ground could be further developed. To achieve that, the report profiled hundreds of relevant companies and investors, provided an overview of major UK Longevity non-profits and research labs, identified major industry trends, used comprehensive infographics to distill industry data and conclusions into easily understandable summaries, and offered guidance on how various UK Longevity Industry stakeholders and government officials could work to strengthen the industry and assist the UK to reach its full potential as a global Longevity Industry Hub.

One of the strongest conclusions to come out of the report was that the United Kingdom has enough resources in each of the three most crucial sectors for Longevity - Biotechnology, Artificial Intelligence and the Financial Industry - to be in a strong position to succeed, but that the nation must focus on cross-sector collaboration and synergetic convergence.

## Conclusion: The UK Needs to Focus on the Formation of Dedicated Longevity Governance Bodies and Creation of Longevity Industry Guidance

The publication of the First Edition of this report in July 2018 coincided with the launch and development of the UK Government's Healthy Ageing Industrial Strategy Challenge Fund, as well as private initiatives such as the establishment of the London AgeTech and Longevity Hub. However Q3 and Q4 of 2018 became a period of accelerated industry development for this sector.

Given this rapid progress, and in order to obtain a more quantitative understanding of these new developments, it became necessary to reassess, update, upgrade and extend the analysis of trends, insights and major conclusions of the report, and to link it more closely to progress made in Q4 2018. We are witnessing a period of accelerated developments in this sector, and all signs indicate that this trend will continue into 2019.

# Longevity Industry in UK Landscape Q4 2018

## Personalized Medicine

Companies - 260  
Investors - 250  
Non-Profits - 10  
Research Labs - 10

Investors  
Companies  
Non-Profits

## AgeTech

## Research Labs

## Preventive Medicine


## Regenerative Medicine

**AGING ANALYTICS AGENCY**

**DEEP KNOWLEDGE ANALYTICS**

**Longevity UK**

**Biogerontology Research Foundation**  
Prevent. Restore. Preserve.



## Scientifically-Validated Lifestyle Recommendation




## Prosthetics



## Nutraceuticals



## Biomarkers



## Progressive Wellness



## Gene therapy



## Research



## Regenerative Medicine



## AgeTech



## Other



260 Companies

## Microbiome



## Neurotech



## Longevity Industry in UK Q4 2018

## Personalised Medicine



## Preventive medicine



## Diagnostics



## Drug Discovery



## Geroprotectors



## Cell Therapies



LongevityUK

Consulting on Advanced Biologicals

ORTHOX

AGING ANALYTICS AGENCY

## JOURNALS



## RESEARCH LABS



**Non-Profits - 50**  
**Journals - 25**  
**Research Labs - 25**  
**Conferences - 20**  
**Media entities - 10**

## MEDIA ENTITIES



**The Science of Longevity in UK Landscape Overview Q4 2018**

## CONFERENCES



## NON-PROFITS






# UK Longevity Influencers

## Top Longevity Scientists and Experts



David Sinclair



Baroness Sally Greengross OBE



Eric Kihlstrom



Helen Whately



John Bell



Matt Hancock



Charles Alessi



Aubrey de Grey



Jim Mellon




Tina Woods



Dmitry Kaminskiy



Narendra Patel



Malcolm Jackson



Tom Kirkwood



George P. Willis



Helen R. Griffiths



Martin Green



Anders Sandberg




Tim Spector



Ben Franklin



Andrew Scott



Qing-Jun Meng



Ilora Gillian Finlay



Leslie Arnold Turnberg



Dame Denise Platt



Philippa Whitford



Linda Partridge



David Kipling



Paul Keith Potter



Julia Neuberger



John Speakman



Suzanne Wait




Jon Date



Paul Thornalley



Janet Thornton



Manlio Vinciguerra



Thomas von Zglinicki



William Bains



Richard Barker



Richard Faragher



Robert Freitas



David Gems



Andrew Krentz




Aisling Burnand



J. P. de Magalhaes



Anne McArdle



Cleo Bishop



Dr Richard Siow



John Pattison



Maggie Throup



Peter Adams



Janet M. Lord



Colin Blakemore



Sally-Marie Bamford



David Amess

# Aging Analytics Agency's Global Longevity Reports



In 2018, Aging Analytics Agency systematised the Longevity Industry for the first time in a series of reports providing a comprehensive assessment of the global Longevity Industry. Our first report, *Longevity Industry Landscape Overview 2018 Volume I: The Science of Longevity*, standing at 760 pages, identified the emerging technologies and scientific developments which could be utilized against ageing. The first half of that report tied together various threads of progress into a coherent narrative, and described the interrelation of biomedical gerontology, regenerative medicine, precision medicine, and artificial intelligence. The second half profiled 650 research hubs, non-profits, leading scientists, conferences, databases, books and journals. The report utilised infographics to illustrate where research institutions stood in relation to each other.

*Longevity Industry Landscape Overview 2018 Volume II: The Business of Longevity*, is a 650-page report that offers a more comprehensive look at the key players, companies, investors and influencers which comprise the emerging global Longevity Industry, profiles 100 Longevity companies and 100 investors, as well as the most prominent individual longevity investors and thought leaders. It provides an overview of the Longevity Industry, its rise in 2016 and it's rapid emergence in 2017-2018, forecasts the major trends and developments in the industry in the years to come, and offers a detailed discussion on the major risks, roadblocks, and issues which may jeopardize the credibility and success of the industry.

The *Longevity Industry Landscape Overview* reports classify various sectors of the Longevity industry broader than what was typical previously. The diagram shown on this slide was created to illustrate the framework of that classification and to provide a breakdown of sub-sectors within each of the four major sectors of the industry. In addition to the science of ageing, the report classifies the emerging technologies of advanced Biomedicine, the AgeTech sector (consisting of non-biomedical technologies that can assist elderly people in maintaining quality of life), as well as the financial sphere as legitimate niches of the expanding Longevity Industry.

